455 Adverse Events: The FDA's Safety Case Against Compounded Semaglutide, Examined

The FDA's 503B exclusion proposal cites hundreds of adverse events. But what do the reports actually show? We looked at the data the FDA didn't contextualize.

The Numbers in the Proposal

The FDA's April 30, 2026 Federal Register notice cited more than 455 adverse event reports linked to compounded semaglutide and more than 320 reports associated with compounded tirzepatide as of early 2025. These numbers feature prominently in the agency's safety rationale for the 503B exclusion.

Numbers without context are alarming by design. Let's add the context.

What the Reports Actually Show

Dosing Errors, Not Formulation Failures

The FDA's own description reveals that many of the adverse events involved "dosing errors from patients self-administering incorrect doses from multidose vials — some of which required hospitalization." This is a user-error problem with multidose vials, not evidence that the compounded medication itself was dangerous.

Multidose vials require patients to draw their own doses using syringes. Unlike brand-name Wegovy's pre-filled auto-injectors or Ozempic's dial-a-dose pens, compounded vials provide no mechanical dose control. A patient who draws 0.5 mL instead of 0.25 mL gets double the intended dose — with predictable gastrointestinal consequences.

This is a real safety concern. But it's an argument for better delivery systems (pre-filled syringes, for example), not necessarily an argument against the active ingredient or the compounding process itself.

Scale Matters

At peak in 2024, compounded GLP-1 medications represented roughly 30% of the U.S. GLP-1 supply. Millions of prescriptions were filled. In that context, 455 adverse event reports over approximately two years represents a very low reporting rate — lower than many FDA-approved medications.

The FAERS (FDA Adverse Event Reporting System) database also contains thousands of reports for branded Wegovy and Ozempic. Adverse events are expected with any medication — the question is whether the rate and severity for compounded versions is meaningfully different from branded versions. The FDA's proposal doesn't present this comparison.

Counterfeit Concerns Are Separate

The FDA has also raised concerns about "counterfeit products entering the market through online channels." This is a legitimate concern, but counterfeit products are illegal regardless of 503B regulations. Shutting down legitimate compounding doesn't address the counterfeit supply chain — it may actually push more patients toward unregulated sources as legal access narrows.

What This Means for Patients

The adverse event data supports a call for better compounding standards, improved delivery devices, and enhanced pharmacy oversight — not necessarily a complete ban on compounding. But the regulatory framework the FDA is operating under doesn't distinguish between "compounding should be safer" and "compounding should end."

For patients, the practical takeaway is this: if you're using compounded GLP-1 medication from a multidose vial, dose accuracy is critical. Use the exact syringes recommended by your pharmacy, measure carefully, and ask your provider to review your injection technique. Pre-filled syringes, when available from your compounding pharmacy, eliminate the dosing error risk entirely.